TITLE

Moderate ischemic mitral regurgitation (IMR) and metabolic syndrome: where are we now and where are we going?

AUTHOR(S)
Osman, Khalid A.; Ahmed, Mohamed H.
PUB. DATE
January 2006
SOURCE
Cardiovascular Diabetology;2006, Vol. 5, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The metabolic syndrome appears to affect 10% to 25% of adult population worldwide. Several studies have described the association between metabolic syndrome and ischaemic heart disease, however, none linked metabolic syndrome to ischemic mitral regurgitation, a serious clinical problem facing both the cardiologists and cardiac surgeons. Ischemic mitral regurgitation is mitral insufficiency caused by myocardial infarction. The myocardial ischemia can result in altered ventricular geometry, leading to mitral insufficiency. Interestingly metabolic syndrome showed more pronounced alteration of left ventricular geometry and function especially in obese subjects. Presentation of the hypothesis: We have recently proposed that there is link between metabolic syndrome and ischemic mitral regurgitation and associated complications. Operative strategy for moderate ischaemic mitral regurgitation continues to be debated between revascularisation alone and concomitant valve repair at the time of coronary artery bypass surgery. Each of the above group has published studies, with results supporting each argument. Testing the hypothesis: Generally speaking the treatments available for metabolic syndrome are based in both life style modification (dietary advice and advice to increase physical activity) and medical treatment to enhance insulin sensitivity. Randomised controlled trials may show whether the current available treatment of metabolic syndrome may have an impact on moderate ischemic mitral regurgitation. Implications of the hypothesis: Metabolic syndrome was shown to alter left ventricular geometry and therefore it is possible to postulate that the variation in the response of different patients with moderate ischemic mitral regurgitation to current management may be attributed to the absence and presence of metabolic syndrome. Research testing of this hypothesis in the future may reveal whether concomitant treatment of metabolic syndrome will play part in the management of moderate ischemic mitral regurgitation.
ACCESSION #
28682810

 

Related Articles

  • ASSESSING EFFICIENCY OF CYTOKINE THERAPY DURING POST-OPERATIVE PERIOD IN PATIENTS WITH CORONARY ATHEROSCLEROSIS. Silaev, A. A.; Turmova, E. P.; Markelova, E. V.; Gromovoy, R. M.; Golub, I. E.; Shkorik, E. V.; Khelimskiy, A. A. // Pacific Medical Journal / Tihookeanskij Medicinskij Zurnal;2013, Vol. 51 Issue 3, p18 

    The authors have examined 80 patients with ischemic heart disease before and after coronary artery bypass surgery. Before surgery, the cases associated with further post-operative inflammatory complications were characterised by low level of Tlymphocytes, in-creased content of cells with...

  • Neurocognitive outcome after coronary artery bypass surgery using minimal versus conventional extracorporeal circulation: a randomised controlled pilot study. Anastasiadis, Kyriakos; Argiriadou, Helena; Kosmidis, Mary H.; Megari, Kalliopi; Antonitsis, Polychronis; Thomaidou, Evanthia; Aretouli, Eleni; Papakonstantinou, Christos // Heart;Jul2011, Vol. 97 Issue 13, p1082 

    Objective Neurocognitive impairment can be a debilitating complication after cardiac surgery. The aim of this study was to assess the effect of minimal extracorporeal circulation (MECC) versus conventional extracorporeal circulation (CECC) on neurocognitive function after elective coronary...

  • Diffuse coronary artery spasm treated by extracorporeal membrane oxygenation. Smith, Chez; Akowuah, Enoch; Theodore, Sanjay; Brown, Robin // European Journal of Cardio-Thoracic Surgery;Jul2009, Vol. 36 Issue 1, p208 

    Abstract: Diffuse coronary vasospasm is an unpredictable and serious complication following coronary artery bypass surgery. The treatment of this emergency is dependent on patient suitability for angiography and direct injection of vasodilators into the affected vessels. In patients unable to...

  • ‘Conditioning’ the heart during surgery Venugopal, Vinod; Ludman, Andrew; Yellon, Derek M.; Hausenloy, Derek J. // European Journal of Cardio-Thoracic Surgery;Jun2009, Vol. 35 Issue 6, p977 

    Summary: Coronary heart disease (CHD) is the leading cause of death worldwide. Coronary artery bypass graft (CABG) surgery remains the procedure of choice for coronary artery revascularisation in a large number of patients with severe CHD. However, the profile of patients undergoing CABG surgery...

  • Coronary artery bypass surgery in the elderly: is it worthwhile? Manché, Alexander // Malta Medical Journal;2013, Vol. 25 Issue 3, p2 

    Objectives: To evaluate the early outcomes after coronary surgery in the elderly. Methods: A retrospective analysis (April 1995- January 2012) of mortality, morbidity and hospital stay, derived from a single surgeon's practice. Outcomes of patients over 70 (group A, n=785) were compared with...

  • Metabolic syndrome.  // BMJ: British Medical Journal (International Edition);11/19/2005, Vol. 331 Issue 7526, p1153 

    This article reports on how metabolic syndrome raises cardiovascular risk. Insulin resistance appears to be the main force leading to the increased risk of mortality from coronary heart disease among people with metabolic syndrome, which is characterized by hyperinsulinaemia, low glucose...

  • Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome. Vasilios G. Athyros; Dimitri P. Mikhailidis; Evangelos N. Liberopoulos; Anna I. Kakafika; Asterios Karagiannis; Athanasios A. Papageorgiou; Konstantinos Tziomalos; Emmanuel S. Ganotakis; Moses Elisaf // Nephrology Dialysis Transplantation;Jan2007, Vol. 22 Issue 1, p118 

    Background. Metabolic syndrome (MetS) is associated with increased risk for both vascular and chronic kidney disease. Whether statins ameliorate these risks is not established.Methods. This post hoc analysis of the GREek Atorvastatin and Coronary heart disease (CHD). Evaluation (GREACE) examines...

  • The metabolic syndrome and cardiovascular risk: implications for clinical practice. Eddy, D. M.; Schlessinger, L.; Heikes, K. // International Journal of Obesity;May2008 Suppelment 2, Vol. 32, pS5 

    Objective:The clinical importance of the metabolic syndrome (MeS) is confused by the existence of at least three different definitions proposed by prominent organizations, and by a lack of information about the prognostic value of diagnosing a person as having the syndrome by any of the...

  • Insulin Resistance and Atherosclerosis: Is it Time to Measure HOMA-IR to Predict Coronary Artery Disease? Kannan, Lakshmi; Chernoff, Arthur // North American Journal of Medical Sciences;Oct2013, Vol. 5 Issue 10, p615 

    The authors discusses a study which determines the relationship of insulin resistance and severity of the coronary artery disease (CAD). They say that atherosclerosis and insulin resistance plays an important role in predicting CAD. The authors mention that the homeostatic model...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics